You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(01177.HK)附屬獲「拉尼蘭諾」大中華區開發生產商業化獨家許可
阿思達克 09-22 16:35
中生製藥(01177.HK)宣佈,附屬公司正大天晴藥於9月21日與Inventiva S.A.簽訂正式許可協議,可於中國大陸、香港、澳門、臺灣開發、生產並商業化用於治療非酒精性脂肪性肝炎(NASH)和其他潛在的代謝疾病的「拉尼蘭諾」(lanifibranor)。 正大天晴將向Inventiva支付1,200萬美元的首付款,以及最高不超過4,000萬美元的潛在臨牀及註冊裏程碑付款,以獲得該產品在大中華區獨家許可。該產品在大中華區獲批上市後,正大天晴將支付額外商業化裏程碑付款及基於大中華區銷售淨額的分層提成。 公司表示,引進該產品將進一步豐富創新研發管線,完善在NASH領域的佈局,爲中國肝病患者提供更好的治療方案。中生製藥透露,拉尼蘭諾目前正在美國進行III期臨牀試驗,將有望成爲第一個獲得FDA批準治療NASH的口服藥物。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account